NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
ALTOPREV (lovastatin) by Merck & Co. is clinical pharmacology the involvement of low-density lipoprotein cholesterol (ldl-c) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments. First approved in 2002.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTOPREV (lovastatin) is an oral extended-release statin that inhibits HMG-CoA reductase to reduce LDL-C and lower coronary heart disease risk. It is indicated for patients with elevated cholesterol levels who require LDL-C reduction. Lovastatin works by blocking a key enzyme in cholesterol biosynthesis, leading to increased LDL receptor activity and reduced VLDL production.
$0.762MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims, signaling shrinking commercial opportunity and likely team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY The involvement of low-density lipoprotein cholesterol (LDL-C) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments. Epidemiological and clinical studies have established that high LDL-C and low high-density…
Worked on ALTOPREV at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.